Description
Randomized clinical trials have demonstrated that vildagliptin is well tolerated and significantly reduces glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) in type 2 diabetes mellitus (T2DM), both as monotherapy and add-on therapy. Increasingly, there is interest in validating these results in everyday clinical practice. A study published in Diabetes Therapy aimed to evaluate vildagliptin’s effectiveness and tolerability in real-world settings, while also identifying factors influencing drug adherence and the management of T2DM.